These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1323 related items for PubMed ID: 28196450

  • 41. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
    Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M.
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):390-395. PubMed ID: 30948330
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Incidence and susceptibility to therapy-related myeloid neoplasms.
    Leone G, Fianchi L, Pagano L, Voso MT.
    Chem Biol Interact; 2010 Mar 19; 184(1-2):39-45. PubMed ID: 20026017
    [Abstract] [Full Text] [Related]

  • 46. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.
    Blood; 2014 Mar 13; 123(11):1658-64. PubMed ID: 24478403
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 13; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 49. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG, Malmgren JA, Li CI, Calip GS.
    Breast Cancer Res Treat; 2013 Dec 13; 142(3):629-36. PubMed ID: 24265034
    [Abstract] [Full Text] [Related]

  • 50. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK, Tucker MA, Curtis RE.
    JAMA Oncol; 2019 Mar 01; 5(3):318-325. PubMed ID: 30570657
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD, González FA, Villegas A, del Potro E, Díaz Mediavilla J, Martínez R, Alvarez A, Colomé JA.
    Sangre (Barc); 1992 Dec 01; 37(6):429-33. PubMed ID: 1293793
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience.
    Huh HJ, Lee SH, Yoo KH, Sung KW, Koo HH, Kim K, Jang JH, Jung C, Kim SH, Kim HJ.
    Ann Lab Med; 2013 Mar 01; 33(2):97-104. PubMed ID: 23483787
    [Abstract] [Full Text] [Related]

  • 56. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, Estey EH, Shaw CM, Ráčil Z, Mayer J, Zak P, Baer MR, Brunner AM, Szotkowski T, Cetkovsky P, Grimwade D, Walter RB, Burnett AK, Ho AD, Ehninger G, Müller-Tidow C, Platzbecker U, Thiede C, Röllig C, Schulz A, Warsow G, Brors B, Esteve J, Russell NH, Schlenk RF, Levis MJ.
    Br J Haematol; 2021 Mar 01; 192(5):832-842. PubMed ID: 33529373
    [Abstract] [Full Text] [Related]

  • 57. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG, Malmgren JA, Atwood M.
    Cancer; 2004 Oct 01; 101(7):1529-36. PubMed ID: 15378478
    [Abstract] [Full Text] [Related]

  • 58. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
    Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.
    Ann Hematol; 2015 Jan 01; 94(1):23-34. PubMed ID: 25096636
    [Abstract] [Full Text] [Related]

  • 59. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
    Gale RP, Hlatky L, Sachs RK, Radivoyevitch T.
    Leuk Res; 2014 Oct 01; 38(10):1162-4. PubMed ID: 25175829
    [No Abstract] [Full Text] [Related]

  • 60. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R, Yin CC, Miranda RN, Bueso-Ramos CE, Wang XI, Muddasani R, Medeiros LJ, Lu G.
    Cancer Genet; 2013 Oct 01; 206(1-2):42-6. PubMed ID: 23357231
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.